PHOTO
Abu Dhabi-UAE: - National Reference Laboratory (NRL), part of Mubadala’s network of world-class healthcre providers, has been approved by the General Civil Aviation Authority (GCAA) to carry out drug and alcohol testing for pilots, cabin crew, ground staff, air traffic controllers and other safety-sensitive aviation professionals and stakeholders in the UAE.
NRL obtained the stringent certification for its robust testing process, quality control, extensive experience with drug and alcohol testing in other industries, and its established reputation in the UAE and the wider region as a leading reference laboratory.
Aviation is a core sector of the national economy supporting economic diversification and social development. The industry is expected to continue its growth trajectory, contributing approximately 750,000 jobs and AED200 billion to the UAE economy by 2020.[i] As a result, the implementation of global safety standards is a top priority for the GCAA, which continues to work towards improving and developing aviation safety and security standards in the UAE through its Aeromedical Alcohol and Drug Testing Program.
Abdul Hamid Oubeisi, Chief Executive Officer of National Reference Laboratory, said: “NRL is honored to leverage its expertise in enhancing the UAE’s aviation industry and to make available to all operators our lab’s advanced and well-established drug and alcohol testing procedures. We are pleased that our strategic committment to implementing world-class laboratory testing standards can directly serve this important industry and contribute to the General Civil Aviation Authority’s ongoing efforts to ensure all stakeholders in aviation adhere to international safety standards.
“Through our comprehensive occupational health testing suite, from rapid on-site testing to the more advanced laboratory-based testing, we are well equipped to help aviation companies ensure their personnel are fit for duty and capable of carrying out their safety-critical functions.”
-Ends-
About National Reference Laboratory
National Reference Laboratory (NRL) is a Mubadala company created in partnership with and managed by LabCorp, a leading global life sciences company providing comprehensive clinical laboratory services. NRL’s vision is to increase the spectrum, coverage and overall efficiency of laboratory testing, to implement international best practice reference laboratory processes and to set the benchmark for quality standards in the region.
Together with the significant resources of LabCorp, NRL offers a comprehensive menu of more than 4,700 tests, providing a complete solution for all clinical testing needs in an efficient and high-quality environment that reduces both turnaround time and logistics-related costs, compared with other laboratories. The diverse and growing network of NRL currently includes eleven owned and managed laboratories across the UAE. For more information, please visit www.nrl.ae.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of over $10 billion in 2017. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.
Contact:
Name: Dr. Bisera Lakinska, MBA, Marketing Manager
Telephone: +971 4 440 2400; 055 8009912
Email: blakinska@nrl.ae
[i] https://www.khaleejtimes.com/business/aviation/look-ahead-2018-uae-aviation-will-soar-higher
© Press Release 2018Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
